Form 4: NeuroOne Medical Technologies CTO Reports Tax-Related Stock Disposal
Insider Transaction Report
NeuroOne Medical Technologies Corp.'s Chief Technology Officer, Steve Mertens, reported the disposal of 906 common shares at $0.678 per share on June 30, 2025, for tax liability purposes.
Summary
- Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies Corp. (NMTC), reported a transaction on June 30, 2025.
- The transaction involved the disposal of 906 shares of common stock.
- The shares were disposed of at a price of $0.678 per share.
- This disposal was coded as 'F', indicating it was for the payment of tax liability incident to the receipt, exercise, or vesting of a security.
- Following this transaction, Steve Mertens beneficially owns 162,235 shares of common stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine disposal of shares for tax liability, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Steve Mertens granted Power of Attorney to Ronald McClurg, Emily Johns, Phillip Torrence, and Stephanie Swan to prepare, execute, submit, and file SEC forms (including Forms 3, 4, and 5) and manage EDGAR system filings on his behalf. | 06/18/2025 | Enhances efficiency and compliance for insider reporting requirements by delegating filing responsibilities to designated attorneys-in-fact. |
Stakeholder Impact
- Minimal direct impact on shareholders as this is a small, routine tax-related disposal by an insider, not indicative of a change in company fundamentals or strategy.
Key Dates
| Date | Description |
|---|---|
| 06/18/2025 | Date Steve Mertens executed the Power of Attorney. |
| 06/30/2025 | Date of the reported transaction (disposal of common stock by Steve Mertens). |
| 07/02/2025 | Date the Form 4 was signed by Emily Johns, by Power of Attorney. |
Keywords
NeuroOne Medical Technologies, NMTC, Steve Mertens, Chief Technology Officer, Insider Trading, SEC Form 4, Stock Disposal, Common Stock, Tax Liability, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.